Skip to main content
SpringerLink
Log in

Lennox-Gastaut Syndrome: Current Treatments, Novel Therapeutics, and Future Directions

  • Current Perspectives
  • Published:
Neurotherapeutics

Abstract

Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1–2% of epilepsy patients. Seizures in DEE-SSW are caused by a variety of etiologies, and there is a large unmet treatment need as seizures are usually treatment-resistant and individuals are often unable to function independently. The updated definition by the International League Against Epilepsy has established formal diagnostic criteria allowing for more uniform diagnosis. This article provides a review of typical medication management and treatment strategies, including new and developing surgical approaches. Future directions in treatment include expanding genetic testing with the potential for gene therapy and continuously improving surgical options with the goal to prevent progression to DEE-SSW.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lennox Gastaut Syndrome. Available at: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=2382

  2. Gastaut H, Roger J, Soulayrol R, Tassinari CA, Régis H, Dravet C, Bernard R, Pinsard N, Saint-Jean M. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox syndrome. Epilepsia. 1966;7(2):139–79. https://doi.org/10.1111/j.1528-1167.1966.tb06263.x. PMID: 4959714.

    Article  CAS  PubMed  Google Scholar 

  3. Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, Guerreiro M, Gwer S, Zuberi SM, Wilmshurst JM, Yozawitz E, Pressler R, Hirsch E, Wiebe S, Cross HJ, Perucca E, Moshé SL, Tinuper P, Auvin S. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1398–442. https://doi.org/10.1111/epi.17241. Epub 2022 May 3 PMID: 35503717.

    Article  PubMed  Google Scholar 

  4. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989 Jul-Aug;30(4):389–99. https://doi.org/10.1111/j.1528-1157.1989.tb05316.x. PMID: 2502382.

  5. French J, Smith M, Faught E, Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 1999;52(8):1540–5. https://doi.org/10.1212/wnl.52.8.1540. PMID: 10331676.

    Article  CAS  PubMed  Google Scholar 

  6. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004 Apr 27;62(8):1261–73. https://doi.org/10.1212/01.wnl.0000123695.22623.32. PMID: 15111660.

  7. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950–8. https://doi.org/10.1212/01.wnl.0000303813.95800.0d. Epub 2008 Apr 9 PMID: 18401024.

    Article  CAS  PubMed  Google Scholar 

  8. Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108(9):1627–36. https://doi.org/10.1016/j.eplepsyres.2014.08.019. Epub 2014 Sep 2 PMID: 25219353.

    Article  CAS  PubMed  Google Scholar 

  9. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas Park E, Stern J, Hirtz D, Nespeca M, Gidal B, Faught E, French J. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018 Jul 10;91(2):82–90. doi: https://doi.org/10.1212/WNL.0000000000005756. Epub 2018 Jun 13. Erratum in: Neurology. 2018 Dec 11;91(24):1117. PMID: 29898974.

  10. Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, Collins SD, Tracy K, Kormany WN, Abdulnabi R, Riley B, Stolle J. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158–66. https://doi.org/10.1111/j.1528-1167.2008.01935.x. Epub 2008 Dec 15 PMID: 19170737.

    Article  CAS  PubMed  Google Scholar 

  11. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA; OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011 Oct 11;77(15):1473–81. https://doi.org/10.1212/WNL.0b013e318232de76. Epub 2011 Sep 28. PMID: 21956725.

  12. Montouris G, Aboumatar S, Burdette D, Kothare S, Kuzniecky R, Rosenfeld W, Chung S. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients. Epilepsy Behav. 2020 Sep;110:107146. https://doi.org/10.1016/j.yebeh.2020.107146. Epub 2020 Jun 18. PMID: 32563898.

  13. Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017;29(8):505. https://doi.org/10.3389/fneur.2017.00505. PMID:29085326;PMCID:PMC5649136.

    Article  Google Scholar 

  14. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018 May 17;378(20):1888–1897. https://doi.org/10.1056/NEJMoa1714631. PMID: 29768152.

  15. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Mar 17;391(10125):1085–1096. https://doi.org/10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26. PMID: 29395273.

  16. Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B; FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 21;394(10216):2243–2254. https://doi.org/10.1016/S0140-6736(19)32500-0. Epub 2019 Dec 17. PMID: 31862249.

  17. Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020 Mar 1;77(3):300–308. https://doi.org/10.1001/jamaneurol.2019.4113. PMID: 31790543; PMCID: PMC6902175.

  18. Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, Guerrini R, Zuberi SM, Nabbout R, Riney K, Shore S, Agarwal A, Lock M, Farfel GM, Galer BS, Gammaitoni AR, Davis R, Gil-Nagel A. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554–64. https://doi.org/10.1001/jamaneurol.2022.0829. PMID:35499850;PMCID:PMC9062770.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Auvin S, Dozieres B, Ilea A, Delanoë C. Use of perampanel in children and adolescents with Lennox-Gastaut syndrome. Epilepsy Behav. 2017;74:59–63. https://doi.org/10.1016/j.yebeh.2017.05.036. Epub 2017 Jul 14 PMID: 28715780.

    Article  PubMed  Google Scholar 

  20. Study of perampanel as adjunctive treatment for inadequately controlled seizures associated with Lennox-Gastaut syndrome. https://clinicaltrials.gov/ct2/show/results/NCT02834793?term=perampanel&cond=Lennox+Gastaut+Syndrome&draw=2&rank=1

  21. Falcicchio G, Lattanzi S, Negri F, de Tommaso M, La Neve A, Specchio N. Treatment with cenobamate in adult patients with Lennox-Gastaut syndrome: a case series. J Clin Med. 2022;12(1):129. https://doi.org/10.3390/jcm12010129. PMID:36614931;PMCID:PMC9821211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Nishi T, Kondo S, Miyamoto M, Watanabe S, Hasegawa S, Kondo S, Yano J, Watanabe E, Ishi T, Yoshikawa M, Ando HK, Farnaby W, Fujimoto S, Sunahara E, Ohori M, During MJ, Kuroita T, Koike T. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020;10(1):17081. https://doi.org/10.1038/s41598-020-74036-6. PMID:33051477;PMCID:PMC7553946.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, Asgharnejad M, Dlugos D. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Epilepsia. 2022 Oct;63(10):2671–2683. https://doi.org/10.1111/epi.17367. Epub 2022 Aug 4. PMID: 35841234; PMCID: PMC9804149.

  24. Liu Y, Yohrling GJ, Wang Y, Hutchinson TL, Brenneman DE, Flores CM, Zhao B. Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res. 2009;83(1):66–72. https://doi.org/10.1016/j.eplepsyres.2008.09.006. Epub 2008 Nov 14 PMID: 19013768.

    Article  CAS  PubMed  Google Scholar 

  25. Lee CY, Lee ML, Shih CC, Liou HH. Carisbamate (RWJ-333369) inhibits glutamate transmission in the granule cell of the dentate gyrus. Neuropharmacology. 2011;61(8):1239–47. https://doi.org/10.1016/j.neuropharm.2011.07.022. Epub 2011 Jul 30 PMID: 21824485.

    Article  CAS  PubMed  Google Scholar 

  26. Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A, Schmitt J, Yuen E, Reines S, Haas M. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures. Neurology. 2008;71(20):1586–93. https://doi.org/10.1212/01.wnl.0000334751.89859.7f. PMID: 19001248.

    Article  CAS  PubMed  Google Scholar 

  27. Halford JJ, Ben-Menachem E, Kwan P, Ness S, Schmitt J, Eerdekens M, Novak G. A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia. 2011;52(4):816–25. https://doi.org/10.1111/j.1528-1167.2010.02960.x. Epub 2011 Feb 14 PMID: 21320109.

    Article  CAS  PubMed  Google Scholar 

  28. Sperling MR, Greenspan A, Cramer JA, Kwan P, Kälviäinen R, Halford JJ, Schmitt J, Yuen E, Cook T, Haas M, Novak G. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epilepsia. 2010;51(3):333–43. https://doi.org/10.1111/j.1528-1167.2009.02318.x. Epub 2009 Oct 27 PMID: 19863578.

    Article  CAS  PubMed  Google Scholar 

  29. Carisbamate in adult & pediatric subjects with Lennox-Gastaut syndrome. https://clinicaltrials.gov/ct2/show/NCT04062981?term=lennox+gastaut&cond=carisbamate&draw=2&rank=1.

  30. Venzi M, David F, Bellet J, Cavaccini A, Bombardi C, Crunelli V, Di Giovanni G. Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures. Neuropharmacology. 2016 Sep;108:292–304. https://doi.org/10.1016/j.neuropharm.2016.04.016. Epub 2016 Apr 13. PMID: 27085605; PMCID: PMC4920646.

  31. Tolete P, Knupp K, Karlovich M, DeCarlo E, Bluvstein J, Conway E, Friedman D, Dugan P, Devinsky O. Lorcaserin therapy for severe epilepsy of childhood onset: a case series. Neurology. 2018 Oct 30;91(18):837–839. doi: https://doi.org/10.1212/WNL.0000000000006432. Epub 2018 Sep 26. PMID: 30258026; PMCID: PMC6207415.

  32. Fisher R, Salanova V, Witt T, Worth R, Henry T, Gross R, Oommen K, Osorio I, Nazzaro J, Labar D, Kaplitt M, Sperling M, Sandok E, Neal J, Handforth A, Stern J, DeSalles A, Chung S, Shetter A, Bergen D, Bakay R, Henderson J, French J, Baltuch G, Rosenfeld W, Youkilis A, Marks W, Garcia P, Barbaro N, Fountain N, Bazil C, Goodman R, McKhann G, Babu Krishnamurthy K, Papavassiliou S, Epstein C, Pollard J, Tonder L, Grebin J, Coffey R, Graves N; SANTE Study Group. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010 May;51(5):899–908. https://doi.org/10.1111/j.1528-1167.2010.02536.x. Epub 2010 Mar 17. PMID: 20331461.

  33. Ilyas A, Pizarro D, Romeo AK, Riley KO, Pati S. The centromedian nucleus: anatomy, physiology, and clinical implications. J Clin Neurosci. 2019;63:1–7. https://doi.org/10.1016/j.jocn.2019.01.050. Epub 2019 Feb 28 PMID: 30827880.

    Article  PubMed  Google Scholar 

  34. Tyvaert L, Chassagnon S, Sadikot A, LeVan P, Dubeau F, Gotman J. Thalamic nuclei activity in idiopathic generalized epilepsy: an EEG-fMRI study. Neurology. 2009;73(23):2018–22. https://doi.org/10.1212/WNL.0b013e3181c55d02. PMID: 19996076.

    Article  CAS  PubMed  Google Scholar 

  35. Velasco AL, Velasco F, Jiménez F, Velasco M, Castro G, Carrillo-Ruiz JD, Fanghänel G, Boleaga B. Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome. Epilepsia. 2006;47(7):1203–12. https://doi.org/10.1111/j.1528-1167.2006.00593.x. PMID: 16886984.

    Article  PubMed  Google Scholar 

  36. Dalic LJ, Warren AEL, Bulluss KJ, Thevathasan W, Roten A, Churilov L, Archer JS. DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome (ESTEL trial). Ann Neurol. 2022 Feb;91(2):253–267. https://doi.org/10.1002/ana.26280. Epub 2021 Dec 28. Erratum in: Ann Neurol. 2022 Apr 12; PMID: 34877694.

  37. Kwon CS, Schupper AJ, Fields MC, Marcuse LV, La Vega-Talbott M, Panov F, Ghatan S. Centromedian thalamic responsive neurostimulation for Lennox-Gastaut epilepsy and autism. Ann Clin Transl Neurol. 2020 Oct;7(10):2035–2040. https://doi.org/10.1002/acn3.51173. Epub 2020 Aug 29. PMID: 32860345; PMCID: PMC7545608.

  38. RNS System LGS feasibility study. ClinicalTrials.gov Identifier: NCT05339126. https://clinicaltrials.gov/ct2/show/NCT05339126

  39. Zhang L, Wang Y. Gene therapy in epilepsy. Biomed Pharmacother. 2021 Nov;143:112075. https://doi.org/10.1016/j.biopha.2021.112075. Epub 2021 Sep 3. PMID: 34488082.

Download references

Author information

Authors and Affiliations

  1. Section of Child Neurology, Children’s Hospital Colorado, Anschutz School of Medicine, University of Colorado, Aurora, CO, USA

    Julie A. Nelson & Kelly G. Knupp

Authors
  1. Julie A. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly G. Knupp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie A. Nelson.

Ethics declarations

Conflict of Interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nelson, J.A., Knupp, K.G. Lennox-Gastaut Syndrome: Current Treatments, Novel Therapeutics, and Future Directions. Neurotherapeutics 20, 1255–1262 (2023). https://doi.org/10.1007/s13311-023-01397-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13311-023-01397-x

Keywords

Search

Navigation